Suramin sodium for injectable aqueous dosage forms is received as a hygroscopic, pale-yellow to beige powder and is typically dissolved under nitrogen-blanketed water for injection to a working concentration of 10% w/v. Clarification is performed in a stirred stainless-steel vessel with a peristaltic pump attached to a polyethersulfone membrane filter; nylon membranes are not recommended unless filter binding studies demonstrate recovery above 95% of the labeled assay. The solution pH is adjusted with 1 M sodium hydroxide or hydrochloric acid and held within pH 5.5–7.0 to reduce hydrolytic degradation of the sulfonated naphthylurea backbone during extended hold times. Degassing under vacuum before filling is applied to avoid oxygen-induced colour development, and the primary packaging is amber borosilicate Type I glass with a halobutyl rubber stopper. Release testing follows Ph. Eur. 2.2.1 for clarity and degree of coloration, Ph. Eur. 2.9.19 for sub-visible particulate contamination, Ph. Eur. 2.6.14 for bacterial endotoxins, and Ph. Eur. 2.6.1 for sterility. Filter validation with the actual production fluid must be repeated when the batch size is changed because the high surface activity of the polyanionic molecule can associate with membrane polymers and reduce effective pore size. The finished injectable is used in equine trypanosomiasis caused by Trypanosoma evansi or Trypanosoma equiperdum, and the withdrawal period is established under national residue-control requirements. Incompatibilities are observed with cationic drug substances and with multivalent cations at elevated concentrations, so rinsing of the compounding line between batches is specified in the master production record.

For ambulatory field treatment of camelid and equine trypanosomiasis, the liquid injection is converted into a lyophilised powder to reduce the transport weight and remove the need for continuous cold-chain storage. The process begins with a filtered 10% w/v solution to which a cryoprotectant is added, usually mannitol or trehalose, at 20–50 g/L. The freeze concentrate is characterised by differential scanning calorimetry; because published collapse temperatures for this specific formulation are limited, primary drying is designed conservatively with a shelf temperature below -35°C and a chamber pressure between 50 µbar and 150 µbar. Batch records record product temperature at the edge and centre of the shelf because freeze-drying front heterogeneity is the main failure mode at full shelf load. Secondary drying is held until residual moisture by Karl Fischer titration is below a stability-linked limit; for similar hygroscopic lyophilisates a limit of 1.0% w/w is often used, but the exact value must be justified by degradation studies. The lyophilised cake is reconstituted with water for injection to a final volume corresponding to 10% w/v suramin sodium. After reconstitution, the solution should be inspected for undissolved particles; slow reconstitution or caking at the vial base indicates insufficient sublimation or inadequate sealing with high-moisture stoppers. Vial leakage during shipping under tropical humidity is a further batch-failure mode, and bromobutyl stoppers with an aluminium flip-off seal are specified because the API readily sorbs moisture above 60% relative humidity.

What Limits the Infusion Concentration for Large Camelid Trypanosomiasis Protocols?

When a 10% w/v concentrate is diluted for slow intravenous infusion, the critical process variable is not solubility but osmolality and venous tolerability. The undiluted injection is strongly hyperosmolar; routine practice is to dilute the prescribed dose with 0.9% w/v sodium chloride injection to reduce endothelial irritation, but calcium-containing fluids and lactated Ringer’s solution are avoided because the polyanionic molecule may form insoluble calcium complexes or associate with multivalent cations. Dilution should be conducted immediately before administration; the admixture is monitored for haze, precipitation, or pH shift because suramin sodium can act as a weak acid and its solubility may be altered by pH excursions below 5.0. A low-protein-binding in-line filter can be placed in the administration set, but filter validation is required due to surface adsorption. For multidose presentations, preservative efficacy testing is performed according to Ph. Eur. 5.1.3, and the preservative must not increase sub-visible particle burden during the in-use period. Single-dose vials avoid preservative-related particle burden and are preferred for large animals because the full dose is usually consumed at one time. The finished product is a ready-to-dilute solution for camelid trypanosomiasis due to Trypanosoma evansi, supplied in Type I glass bottles with an outer carton label stating protection from light. Published data for this specific infusion configuration is limited; therefore dilution ratio and administration rate are validated in the target species under veterinary supervision rather than extrapolated from small-laboratory models.

Oral Tablet and Capsule Performance Boundaries in Suramin Delivery

The high molecular weight of 1429.2 g/mol and six ionised sulfonate groups restrict passive transcellular diffusion and produce low and variable oral absorption. Tablets and capsules are therefore not a conventional commercial veterinary presentation; they arise mainly in controlled pharmacokinetic studies or are compounded for non-food animals under extra-label use. Direct compression trials with lactose monohydrate or dicalcium phosphate dihydrate have shown that the polyanionic active ingredient can adhere to metal surfaces and may interact with cationic excipients, causing weight variation and assay drift. Binding with magnesium stearate or cationic polymers should be avoided unless migration and dissolution testing demonstrate equivalence. If an oral capsule is produced, the critical in-process controls are blend uniformity, water activity, and disintegration; the capsule shell should be selected for low water content because the API is hygroscopic. Taste masking, not bioavailability enhancement, is the main formulation challenge because the oral route is limited by membrane permeability rather than drug release. Terminal sterility is not required for oral dosage forms; microbial quality is tested according to Ph. Eur. 2.6.12 and Ph. Eur. 2.6.13 or harmonised USP <61>/<62>. Published data for this specific configuration is limited; bioavailability and clinical efficacy must be investigated in the target animal before an oral product is presented as a valid alternative to injection.

Premix Stability Is Governed by Moisture Sorption Rather Than Thermal Exposure

Investigational granular or premix presentations for non-food animals are manufactured by fluid-bed wet granulation rather than high-shear wet granulation, because the API dissolves rapidly in water and can harden into intractable lumps when overwetted. The dry blend is charged into a fluid-bed processor with inlet air dewpoint below 10°C and product temperature below 40°C; purified water is sprayed at a rate that maintains the bed in the suspended state. After spraying, granules are dried to a loss-on-drying value below 3.0% w/w. These granules are intended for extemporaneous dose preparation, not for commercial medicated feeds in food-producing animals because no maximum residue limit has been established in relevant regions. Sorption isotherms show that the material picks up moisture above 60% relative humidity, leading to clumping and darkened speckles in storage. Packaging therefore uses aluminium foil pouches with a desiccant sachet. The chemical compatibility of suramin sodium with mineral carriers such as calcium carbonate or dicalcium phosphate is poor at high humidity, and such carriers are replaced by lactose monohydrate or microcrystalline cellulose. Batch release includes sieve analysis, loss on drying, and assay, with the assay extraction solvent demonstrated to recover the active from the carrier matrix. Powder mixing lines must be dry-cleaned rather than wet-cleaned between products because residual moisture on stainless-steel contact surfaces can prematurely dissolve a small fraction of API and leave a sticky deposit on the next batch.

When Lyophilised Powder Is Replaced by Ready-to-Use Solution in Tropical Field Settings

Stability problems in tropical field settings are dominated by light exposure and seal integrity rather than bulk chemical degradation. The ready-to-use solution is stored in amber glass, and the label explicitly states protection from light because photodegradation can intensify the yellow colour and increase related substances. Stability chambers used for product development are operated at 25°C/60% RH and 40°C/75% RH according to VICH GL3, with additional in-use testing after first opening to determine the maximum safe administration window. Elastomeric closure compatibility is evaluated under Ph. Eur. 3.2.9 and USP <381> because sulfonated aromatic compounds can alter the extractable profile of halobutyl stoppers at elevated temperature, producing sub-visible particles. Vial headspace oxygen is kept below 2% by nitrogen flushing, and residual oxygen is measured by electrochemical oxygen analysis during line setup. The solution is filled under laminar airflow with a maximum hold time defined by bioburden monitoring, and the bulk solution is stored under validated conditions to prevent microbial proliferation. Transportation of liquid product into remote regions requires insulated packaging with temperature loggers; freeze-thaw cycles are avoided because the resulting pH gradients can produce localised precipitation. If the product is exposed to accidental freezing, the vial is discarded unless a freeze-thaw validation study demonstrates full redissolution and acceptable sub-visible particulate counts after warming to room temperature.